Press coverage about Exactech (NASDAQ:EXAC) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Exactech earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.2780898001385 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Exactech (NASDAQ EXAC) opened at $50.45 on Friday. The company has a market cap of $724.77, a price-to-earnings ratio of 5,045.00, a PEG ratio of 3.65 and a beta of 1.02. Exactech has a 1-year low of $23.30 and a 1-year high of $50.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09.
Exactech (NASDAQ:EXAC) last announced its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). The business had revenue of $61.40 million during the quarter, compared to analyst estimates of $61.78 million. Exactech had a net margin of 0.18% and a return on equity of 7.22%. analysts predict that Exactech will post 1.29 earnings per share for the current fiscal year.
EXAC has been the topic of a number of research analyst reports. Robert W. Baird set a $34.00 price objective on shares of Exactech and gave the stock a “buy” rating in a report on Sunday, October 15th. Zacks Investment Research raised shares of Exactech from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. ValuEngine cut shares of Exactech from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Gabelli cut shares of Exactech from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, Sidoti cut shares of Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Six equities research analysts have rated the stock with a hold rating, Exactech presently has an average rating of “Hold” and an average target price of $49.00.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-exactech-exac-share-price.html.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.